Executive Summary
The framework for designing and executing IND-enabling safety pharmacology programs for small interfering RNA (siRNA) therapeutics requires GxP-compliant environments. The focus is on identifying potential adverse effects on major physiological systems (cardiovascular, respiratory, central nervous) prior to first-in-human studies. A tailored strategy addresses the unique biological activity and delivery mechanisms, such as Lipid Nanoparticles (LNPs), associated with RNA-based next-generation therapies.
Frequently Asked Questions
Q: What are the primary considerations for IND-enabling toxicology studies involving siRNA constructs?
The primary considerations extend beyond standard toxicology endpoints. For siRNA, the program must rigorously evaluate potential hybridization-dependent off-target effects, innate immune stimulation by the RNA duplex or its delivery vehicle, and the pharmacology of the delivery system itself, such as an LNP. Characterizing non-target tissue biodistribution is also a key component of the safety assessment.
Q: What is the role of GxP conditions in the safety assessment of RNA therapeutics?
GxP conditions ensure that all nonclinical safety data submitted to regulatory bodies like the FDA and MHRA are reliable, reproducible, and of the highest integrity. For RNA therapeutics, this includes stringent controls over assay validation for measuring target knockdown and potential immunogenicity, ensuring the data accurately reflects the safety profile and supports a successful IND submission.
Q: How does Franklin Biolabs select appropriate animal models for siRNA safety studies?
Model selection is driven by scientific rationale, focusing on species where the siRNA target sequence is conserved and the underlying biology is relevant to the human indication. For certain programs, nonhuman primate models are used to assess complex immune responses and provide the most predictive data for human clinical outcomes.
A standard, templated preclinical testing strategy does not exist for siRNA therapeutics. The transient nature of siRNA and the complexity of its delivery systems demand a data-driven preclinical program tailored to the specific modality and its target indication. Our approach focuses on de-risking the asset by building a comprehensive safety profile that satisfies global regulatory expectations, including those for FDA and MHRA submissions.
The core safety pharmacology battery for an siRNA therapeutic assesses its potential effects on vital functions. This evaluation includes:
* **Cardiovascular System:** Continuous telemetry in appropriate large animal models to monitor blood pressure, heart rate, and ECG parameters.
* **Central Nervous System (CNS):** A functional observational battery (FOB) to detect any changes in behavior, motor function, or sensory responses.
* **Respiratory System:** Whole-body plethysmography to measure respiratory rate and tidal volume.
Extrapolating from Advanced Modality Experience
While siRNA presents unique challenges, the principles of rigorous nonclinical safety evaluation are universal. Experience with other advanced modalities informs our strategic approach. For instance, defining a wide therapeutic window was a key outcome in nonclinical studies of AAV-mediated gene therapies, which directly supported their advancement to Phase 1 trials (PMID: 28319445). This same principle of clearly establishing the safety margin is applied to every siRNA program.
Understanding the impact of administration parameters on vector pharmacokinetics and safety is a translatable lesson. Investigations into AAV vector infusion protocols in nonhuman primates revealed important trends influencing safety and biodistribution (PMID: 27933307). This knowledge directly informs the design of infusion protocols for LNP-delivered siRNA, minimizing potential infusion-related reactions and optimizing delivery.
A Commitment to Animal Welfare in Research
All in vivo studies are conducted in our >100,000 sq ft facilities under the guidance of board-certified veterinarians and skilled technical staff. We are committed to the highest ethical standards and the 3Rs principle (Replacement, Reduction, and Refinement), ensuring the well-being of all laboratory animals involved in our research programs.
Our scientific leadership and core preclinical team have a 100% successful IND rate since 2019, a track record established prior to the formal launch of Franklin Biolabs in 2024. This history, combined with our work with partners like Moderna, enables us to guide sponsors from candidate selection to an IND-ready state in 18-24 months.
This work is a component of our broader capabilities in Preclinical | Translational Services.
Featured Video: RESPONSIBILITY AND ANIMAL WELFARE
This video details Franklin Biolabs’ commitment to animal care and welfare, highlighting our adherence to international guidelines and the three Rs (Reduce, Refine, Replace) of animal research.
Watch Video Clip
